A Study to Determine the Effect of Tiotropium + Olodaterol Fixed Dose Combination on Exercise Endurance Time During Constant Work Rate Cycle Ergometry Test in COPD

Completed · Phase 3 · Has a placebo group

Conditions studied: Pulmonary Disease, Chronic Obstructive

In brief

The primary objective of this study is to compare the effects of orally inhaled tiotropium + olodaterol fixed dose combination (2.5/5 µg; 5/5 µg) with placebo on exercise tolerance after 12 weeks of treatment in patients with COPD.

Key facts

Study ID

NCT01525615

Run by

Boehringer Ingelheim

People needed

404

Starts

2012-02-01

Expected to finish

2013-09-01

Last updated by the study team

2016-08-29

Who can join

Age: 40 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• All patients must sign an informed consent consistent with ICH-GCP guidelines prior to participation in the trial, which includes medication washout and restrictions.
• All patients must have a diagnosis of chronic obstructive pulmonary disease and must meet the following spirometric criteria:
• Patients must have relatively stable airway obstruction with, at visit 1:
• a post-bronchodilator 30% <= FEV1 <80% of predicted normal (ECSC) and a post-bronchodilator FEV1/FVC <70% at Visit 1
• Male or female patients, between 40 and 75 years (inclusive) of age on day of signing informed consent.
• Patients must be current or ex-smokers with a smoking history of more than 10 pack years Patients who have never smoked cigarettes must be excluded.
• Patients must be able to perform technically acceptable pulmonary function tests (spirometry), must be able to complete multiple symptom-limited cycle ergometry tests (and for a subset also shuttle walk tests), as required in the protocol.
• Patients must be able to inhale medication in a competent manner from the RESPIMAT inhaler and from a metered dose inhaler (MDI).

You may not qualify if…

• Patients with a significant disease other than COPD
• Patients with clinically relevant abnormal baseline haematology, blood chemistry, or urinalysis; all patients with an SGOT > x2 ULN, SGPT > x2 ULN, bilirubin > x2 ULN or creatinine > x2 ULN will be excluded regardless of clinical condition
• Patients with a history of asthma
• A diagnosis of thyrotoxicosis
• A diagnosis of paroxysmal tachycardia (>100 beats per minute)
• A history of myocardial infarction within 1 year of screening visit (Visit 1)
• Unstable or life-threatening cardiac arrhythmia
• Hospitalized for heart failure within the past year
• Known active tuberculosis
• A malignancy for which patient has undergone resection, radiation therapy or chemotherapy within last five years
• A history of life-threatening pulmonary obstruction and patients with chronic respiratory failure
• A history of cystic fibrosis
• Clinically evident bronchiectasis
• A history of significant alcohol or drug abuse
• Any contraindications for exercise testing
• Patients who have undergone thoracotomy with pulmonary resection
• Patients being treated with any oral ß-adrenergics
• Patients being treated with oral corticosteroid medication at unstable doses (i.e., less than six weeks on a stable dose) or at doses in excess of the equivalent of 10 mg of prednisone per day or 20 mg every other day
• Patients who regularly use daytime oxygen therapy for more than one hour per day and in the investigator's opinion will be unable to abstain from the use of oxygen therapy during clinic visits
• Patients who have completed a pulmonary rehabilitation program in the six weeks prior to the screening visit (Visit 1) or patients who are currently in a pulmonary rehabilitation program
• Patients who have a limitation of exercise performance as a result of factors other than fatigue or exertional dyspnoea or morbid obesity
• Patients with an endurance time >=25 minutes during the training (Visit 2) or baseline (Visit 3) constant work rate cycle ergometry
• Patients who have taken an investigational drug within one month or six half lives (whichever is greater) prior to screening visit (Visit 1)
• Patients with known hypersensitivity to ß-adrenergic drugs, anticholinergic drugs, BAC, EDTA or any other component of the RESPIMAT inhalation solution delivery system
• Pregnant or nursing women

Where it is running

• 1237.15.01512 Boehringer Ingelheim Investigational Site — Hartford, Connecticut, United States
• 1237.15.01506 Boehringer Ingelheim Investigational Site — Springfield, Illinois, United States
• 1237.15.01507 Boehringer Ingelheim Investigational Site — Iowa City, Iowa, United States
• 1237.15.01504 Boehringer Ingelheim Investigational Site — Livonia, Michigan, United States
• 1237.15.01511 Boehringer Ingelheim Investigational Site — Saint Charles, Missouri, United States
• 1237.15.01509 Boehringer Ingelheim Investigational Site — Lebanon, New Hampshire, United States
• 1237.15.01513 Boehringer Ingelheim Investigational Site — Charlotte, North Carolina, United States
• 1237.15.01514 Boehringer Ingelheim Investigational Site — Philadelphia, Pennsylvania, United States
• 1237.15.01516 Boehringer Ingelheim Investigational Site — Pittsburgh, Pennsylvania, United States
• 1237.15.01508 Boehringer Ingelheim Investigational Site — Easley, South Carolina, United States
• 1237.15.01501 Boehringer Ingelheim Investigational Site — Greenville, South Carolina, United States
• 1237.15.01505 Boehringer Ingelheim Investigational Site — Spartanburg, South Carolina, United States
• 1237.15.01502 Boehringer Ingelheim Investigational Site — Union, South Carolina, United States
• 1237.15.01510 Boehringer Ingelheim Investigational Site — Richmond, Virginia, United States
• 1237.15.54502 Boehringer Ingelheim Investigational Site — Buenos Aires, Argentina
• 1237.15.54501 Boehringer Ingelheim Investigational Site — Mendonza, Argentina
• 1237.15.54503 Boehringer Ingelheim Investigational Site — Provincia de Buenos Aires, Argentina
• 1237.15.11501 Boehringer Ingelheim Investigational Site — Hamilotn, Ontario, Canada
• 1237.15.11503 Boehringer Ingelheim Investigational Site — Hamilton, Ontario, Canada
• 1237.15.11504 Boehringer Ingelheim Investigational Site — Kingston, Ontario, Canada
• 1237.15.11505 Boehringer Ingelheim Investigational Site — Montreal, Quebec, Canada
• 1237.15.11502 Boehringer Ingelheim Investigational Site — Ste-Foy, Quebec, Canada
• 1237.15.35851 Boehringer Ingelheim Investigational Site — Helsinki, Finland
• 1237.15.35853 Boehringer Ingelheim Investigational Site — Turku, Finland
• 1237.15.01503 Boehringer Ingelheim Investigational Site — Torrance, California, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.